Welcome to the e-CCO Library Archive!

Filter:
P382. Risk factors for a first abdominal surgical intervention in patients with already established diagnosis of Crohn's disease
Authors:

R. Dudkowiak1, P. Petryszyn1, L. Paradowski1, 1Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland

P382

Prevalence of impaired muscle strength in an IBD outpatient cohort.

Authors:

C. Spooren*, M. Pierik, T. van den Heuvel, E. de Koning, Z. van Mechelen, A. Masclee, D. Jonkers

Maastricht University Medical Center+, Internal Medicine - Division Gastroenterology-Hepatology, Maastricht, Netherlands

P383.

Predictive factors of early infliximab infusion reactions in inflammatory bowel disease

Authors:

C. Duron1, A. Buisson1, B. Pereira2, G. Bommelaer1, 1University Hospital Estaing, Gastroenterology department, Clermont-Ferrand, France, 2DRCI, Biostatistics Unit, Clermont-Ferrand, France

P383. Endoscopy at three months from start of anti‑TNF as a predictor for long-term endoscopic remission in Crohn's disease
P383. Response rates and side effects after 26 weeks of tacrolimus, infliximab or cyclosporine in patients with steroid refractory ulcerative colitis – Swiss IBD cohort study
Authors:

M. Protic1, P. Frei2, Z. Radojicic3, A. Schoepfer4, P. Juillerat5, C. Mottet6, G. Rogler7, C. Beglinger8, F. Seibold1, 1Spital Netz Bern, Gastroenterology, Bern, Switzerland, 2See Spital, Gastroenterology, Horgen, Switzerland, 3Faculty of Organizational Sciences, Statistcs, Belgrade, Serbia, 4Centre hospitalier universitaire Vaudois, Gastroenterology, Lausanne, Switzerland, 5University Hospital Bern Inselspital, Gastroenterology, Bern, Switzerland, 6Hospital Neuchâtel, Gastroenterology, Neuchâtel, Switzerland, 7University Hospital Zürich, Gastroenterology, Zürich, Switzerland, 8University Hospital Basel, Gastroenterology, Basel, Switzerland

P383

Overweight impairs short-term outcomes of laparoscopic IBD surgery. A comparative analysis of 639 consecutive patients.

Authors:

L. Maggiori*1, M. Couturier1, X. Tréton2, Y. Bouhnik2, Y. Panis1

1Beaujon Hospital, Colorectal Surgery, Clichy, France, 2Beaujon Hospital, Gastroenterology, Clichy, France

P384.

Predictive factors of response to prolonged intravenous corticosteroids in patients with acute severe ulcerative colitis

Authors:

D.J. Lee, M.E. Song, S.J. Park, S.P. Hong, T.I. Kim, W.H. Kim, J.H. Cheon, Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea

P384. Effectiveness of smoking cessation in Crohn's disease patients
P384. Relationship between adalimumab concentration and efficacy for the maintenance of clinical remission in pediatric patients with moderate to severe Crohn's disease
Authors:

S. Sharma1, R. Pradhan1, R. Thakkar1, A. Robinson1, J. Hyams2, J. Rosh3, F.M. Ruemmele4, W. Awni1, 1Abbott Laboratories, United States, 2Connecticut Children's Med Ctr, United States, 3NJ Medical School, United States, 4Hôpital Necker-Enfants Malades, France

P384

Golimumab maintenance treatment and fecal calprotectin predict continuous clinical response in ulcerative colitis.

Authors:

W. Reinisch*1, 2, J.-F. Colombel3, W. Sandborn4, B. Feagan5, C. Marano6, R. Strauss6, S. Huyck7, R. Yao7, P. Rutgeerts8, H. Zhang9, F. Cornillie10

1McMaster University, Department of Internal Medicine, Hamilton, Canada, 2Medical University, Department of Internal Medicine III, Vienna, Austria, 3Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States, 4University of California San Diego, Division of Gastroenterology, La Jolla, United States, 5University of Western Ontario, Robarts Research Institute, London, Canada, 6Janssen R&D, LLC, Clinical Development Immunology, Spring House, United States, 7Merck & Co., Inc., Department of Statistics, Merck Research Laboratories, Whitehouse Station, United States, 8University Hospital Gasthuisberg, Division of Gastroenterology, Leuven, Belgium, 9Merck & Co., Inc., Clinical Biostatistics, Biometrics and Reporting, Whitehouse Station, United States, 10MSD International, Immunology Medical Affairs, Luzern, Switzerland

P385.

Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn's disease

Authors:

M. Rosario1, N. Dirks2, M. Gastonguay2, I. Fox1, A. Milton1, 1Takeda Pharmaceuticals International Company, Clinical Pharmacology, Cambridge, United States, 2Metrum Research Group LLC, Biotechnology, Tariffville, United States

P385. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant inflammatory bowel disease patients
P385. Relationship between adalimumab concentration and efficacy for the induction of clinical remission in pediatric patients with moderate to severe Crohn's disease
Authors:

R. Pradhan1, S. Sharma1, R. Thakkar1, A. Robinson1, J. Hyams2, J. Rosh3, F.M. Ruemmele4, W. Awni1, 1Abbott Laboratories, United States, 2Connecticut Children's Med Ctr, United States, 3NJ Medical School, United States, 4Hôpital Necker-Enfants Malades, France

P385

Azathioprine and 6-Mercaptopurine use in the Swiss IBD cohort: adverse effects, causes of discontinuation and risk of "flares" according to 6-TG levels

Authors:

D. Lavrek*1, N. Fournier1, V. Pittet1, D. Müller2, C. Mottet1, 3, 4

1Lausanne University Hospital, Institute of Social & Preventive Medicine (IUMSP), Lausanne, Switzerland, 2Zürich University Hospital, Institute of Clinical Chemistry, Zürich, Switzerland, 3Lausanne University Hospital, Division of Gastroenterology & Hepatology, Lausanne, Switzerland, 4Hôpital Neuchâtelois, Division of Gastroenterology, Neuchâtel, Switzerland

P386.

Pharmacokinetics of laquinimod in patients with active moderate to severe Crohn's disease

Authors:

G. D'Haens1, W.J. Sandborn2, P. Rutgeerts3, J.F. Colombel4, D. Mimrod5, O. Spiegelstein5, K. Brown6, B. Feagan7, 1University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands, 2University of California, UCSD Inflammatory Bowel Disease Center, San Diego CA, United States, 3Catholic University of Leuven, Department of Internal Medicine and Endoscopy, Leuven, Belgium, 4Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, 5Teva Pharmaceuticals, Phase-1 & Clinical Pharmacology Research and Development, Netanya, Israel, 6Teva Pharmaceuticals, Clinical Development Research and Development, Frazer, United States, 7University of Western Ontario, Robarts Clinical Trials Robarts Research Institute, Ontario, Canada

P386. Long term functional results and quality of life after restorative proctocolectomy for ulcerative colitis: A twenty years experience
P386. Refractory inflammatory bowel disease, treated with anti-TNF agents in patients with hepatitis C
Authors:

I. Gubonina1, A. Pershko1, A. Dragun2, 1Military Medical Academy, 2nd Therapy Dpt, St-Petersburg, Russian Federation, 2International Medical Centre “Sogaz”, Out-patient department, St-Petersburg, Russian Federation

P386

Durability of the anti-HBs titers after vaccination against Hepatitis B virus (HBV) in patients with Inflammatory Bowel Disease (IBD)

Authors:

M. Chaparro*1, J. Gordillo2, E. Domènech3, M. Esteve4, M. Barreiro de-Acosta5, A. Villoria6, E. Iglesias-Flores7, M. Blasi2, J.E. Naves8, O. Benítez9, X. Calvet10, V. García-Sánchez7, J.R. Villagrasa11, A.C. Marín1, M. Ramas1, I. Moreno12, J.P. Gisbert1

1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Santa Creu i Sant Pau, Gastroenterology Unit, Barcelona, Spain, 3Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain, 4Hospital Universitario Mutua de Terrassa, Gastroenterology Unit, Terrassa, Spain, 5Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 6Hospital de Sabadell and CIBERehd, Gastroenterology Unit, Sabadell, Spain, 7Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 8Hospital Universitario Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Barcelona, Spain, 9Hospital Universitario Mutua de Terrassa and CIBERehd. , Gastroenterology Unit, Terrassa, Spain, 10Hospital de Sabadell. Corporació Sanitària Universitària Parc Taulí and CIBERehd, Gastroenterology Unit, Sabadell, Spain, 11Hospital Universitario de La Princesa and IIS-IP , Preventive medicine unit, Madrid, Spain, 12Hospital Universitario de La Princesa and IIS-IP , Fundación de Investigación Biomédica, Madrid, Spain

P387.

Persistence of antibodies to infliximab for more than two months strongly predicts loss of response to infliximab in inflammatory bowel diseases

Authors:

M. Leclerc1, H. Marotte2, S. Paul3, E. Del Tedesco1, P. Gonzalo4, J.M. Phelip1, L. Peyrin Biroulet5, X. Roblin1, 1University Hospital, Gastroenterology, Saint Etienne, France, 2University Hospital, Rheumatology, Saint Etienne, France, 3University Hospital, Immunology, Saint Etienne, France, 4University Hospital, Biochimy, Saint Etienne, France, 5CHU de Nancy, Gastroenterologie, Vandoeuvre-les-Nancy, France

P387. Factors associated with successful rescue therapy with infliximab for acute severe ulcerative colitis